Pathophysiology of Schizophrenia and Dementia

Pathophysiology of Schizophrenia and Dementia Schizophrenia currently is conceptualized as a broad syndrome expressed by a heterogeneous group of brain disorders rather than as a single disease entity. In addition, schizophrenia is viewed as the most severe end of a spectrum of schizophrenia-related disorders. Although placed in the category of “functional” psychiatric disorders, schizophrenia is associated primarily with abnormalities of brain neurochemistry, neuroanatomy, and development.

Genetics and intrauterine events likely play the major etiologic role in schizophrenia, with psychosocial stressors serving as precipitating or exacerbating factors. This view is a move away from the psychodynamic theories of the mid-twentieth century and a return to some of the earliest conceptions of the disease. This modern biopsychiatric model has a firm foundation in twin concordance studies and research into the actions of antipsychotic medications on the dopamine systems, and, more recently, serotonin, glutamate, and muscarine systems in the brain.

As a result, antipsychotic medications are now the primary treatment for schizophrenia, with counseling and behavioral therapies playing supportive, but secondary, roles. The dopamine hypothesis suggests that the hallmark neurochemical disturbance is an overactivity of the dopamine system in the brain, particularly that involving the D2 receptors, which are blocked by all antipsychotic drugs (with the possible exception of the newest atypical antipsychotic drugs).

Dopamine overactivity is thought to cause the positive symptoms of the disease. Diminished activity in the prefrontal cortex related to serotonin transmission is associated with the negative symptoms. The efficacy of the new atypical antipsychotics in reversing negative symptoms may be owing to their blockage of specific serotonin receptors. Glutamatergic and, most recently, muscarinic systems have been shown in some studies to be related to both positive and negative schizophrenia symptoms.

Modulation of these systems is at the forefront of research on schizophrenia medication treatment. Dementia is the loss (usually gradual) of mental abilities such as thinking, remembering, and reasoning. It is not a disease, but a group of symptoms that may accompany some diseases or conditions affecting the brain. There are many different types of dementia, each with their own causes. The most common dementia symptoms include loss of memory, confusion, and changes in personality, mood and behavior.

Dementia usually affects older people and becomes more common with age. About 6 in 100 of those over the age of 65 will develop some degree of dementia, increasing to about 20 in 100 of those over the age of 85. Dementia can develop in younger people but is less common, affecting about 1 in 1,000 of those under 65. Although most of the people who develop dementia are over the age of 60, it’s important to remember that dementia is not a normal part of growing old, and older people never develop dementia.